CLINICAL_TRIALS
trial_result
· 2017-03-09
Clinical Trial Update: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma [Phase 2]
Summary
Phase 2 safety study of daratumumab (HuMax-CD38) in multiple myeloma has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-09